Author

F. Sigoillot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 2 Assay:ATAC-seq· 1 Organism:C. elegans· 1 Approach:deep learning· 1 Organism:Drosophila· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Russ· 2 shared R. Maher· 2 shared S. Clarkson· 2 shared A. Bric· 1 shared A. Hadjikyriacou· 1 shared A. Hofmann· 1 shared A. Hyrina· 1 shared A. Li· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Russ

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings

M. Schroeder, M. Renatus, X. Liang, F. Meili, S. Ferrand, F. Gauter, X. Li, F. Sigoillot, S. Gleim, M.-T. Stachyra, J. Thomas, M. Schirle, T. Zoller, D. Begue, P. Lefeuvre, , C. R. Thoma

This study develops DCAF1-based PROTACs to overcome CRBN resistance in targeted protein degradation, demonstrating effective degradation of BTK in CRBN-resistant cells.

bioRxiv · Apr 9, 2023 · PreprintBiochemistry

Multi-Species Phenotypic Screening across Disease Models of Mucolipidosis Type IV

A. Hadjikyriacou, S. Iyer, J. D. Mast, N. DiPrimio, J. Concannon, J. Ketterman, F. Sigoillot, T. P. Rodriguez, F. S. Sam, H. Tsang, M. Prangley, J. Bilen, K. Murthy, T. A. Hartl, C. Antczak, , S. M. Canham

The paper screens a compound library across invertebrate and human models of mucolipidosis IV to identify conserved disease modifiers, finding cyclin-dependent kinase inhibition as a potential therapeutic strategy.

bioRxiv · Mar 5, 2021 · PreprintCell Biology

In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling

Z. Jagani, G. Chenail, K. Xiang, G. Bushold, H.-E. C. Bhang, A. Li, G. Elliott, J. Zhu, A. Vattay, T. Gilbert, A. Bric, R. Kikkawa, V. Dubost, R. Terranova, J. Cantwell, , Haas

This study validates novel BRM/BRG1 ATPase inhibitors as chemical probes for SWI/SNF chromatin remodeling and shows their therapeutic potential in BRG1-mut lung cancers.

bioRxiv · Oct 22, 2019 · PreprintCancer Biology

A genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production

A. Hyrina, C. Jones, D. Chen, S. Clarkson, N. Cochran, P. Feucht, G. Hoffman, A. Lindeman, C. Russ, F. Sigoillot, K. Uehara, L. Xie, D. Ganem, M. Holdorf

The paper uses a genome-wide CRISPR screen to identify ZCCHC14 as a host factor required for hepatitis B surface antigen production and shows it stabilizes HBsAg through RNA tailing with TENT4A/B.

bioRxiv · Jul 30, 2019Microbiology